Follow us on...


Search News Archives
Events
«  »
SMTWTFS
1234567
891011121314
15161718192021
22232425262728
293031 

Biochemistry Conference 2017


GCC Forensic Science Conference


Cleanroom Management Summit


 

Media Partners


 

 


Subscibe to our YouTube channel

 

 

E-Newsletter Month  
Lab Bulletin Monthly Update September view archive
Microscopy & Image Analysis September view archive
Separation Science September view archive
Weekly Update October (3) view archive

For further information or to sign up to receive any of our E-Newsletters click here


MDxHealth Launches CE-Marked SelectMDx IVD PCR Kit and UrNCollect Device

publication date: Jul 7, 2017
 | 
author/source: MDxHealth

MDxHealth SA (Euronext: MDXH.BR) have announced the launch in Europe and other markets of the SelectMDx® for Prostate Cancer in vitro diagnostic (IVD) PCR kit with CE-marked components and CE-marked UrNCollect™ device.

MDxHealthThe IVD PCR kit will enable diagnostic laboratories with manual and automated RNA extraction and PCR platforms to perform the SelectMDx liquid biopsy test in their own facility. The CE-marked UrNCollect device is a unique, user-friendly and compact collection tool that complements the IVD kit by enabling easy and efficient sample collection.

Robustness, reproducibility and interlaboratory performance of SelectMDx was recently published in a technical validation study in Translational Medicine Communications.Urine samples from men scheduled for prostate biopsies due to elevated PSA levels and/or an abnormal digital rectal exam (DRE) or family history of prostate cancer, were tested with SelectMDx. There was less than a two percent difference between the sites’ test results for finding high-grade prostate cancer upon biopsy and samples could be successfully evaluated even after being stored for a year.

Prior studies have validated that SelectMDx predicts the presence of high-grade prostate cancer and helps stratify patients to receive MRI scans or biopsies.

“Many of our current customers are eager to start using the IVD PCR kit so they can run the SelectMDx for Prostate Cancer test in their own labs,” said Dr. Jan Groen, CEO of MDxHealth. “It’s well-timed that our UrNCollect device is launching as a complement to the SelectMDx IVD PCR kit because pilot studies demonstrated that patients and physicians found the device easier to use than traditional urine collection tubes.”

SelectMDx service testing remains available through distribution partners and laboratories that are not equipped to use the IVD PCR kit. Samples are processed at MDxHealth’s state-of-the-art ISO-certified diagnostic facilities in Nijmegen, the Netherlands and Irvine, California, US.


more about MDxHealth


 




Can't find what you are looking for?


Search by company, product or location

Company Name:

Location:

Product:



Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have a product enquiry, please contact the supplier directly.


Lab Bulletin is published by newleaf marketing communications ltd

Promotions